Literature DB >> 6662183

Beta-blocking and electrophysiological effects of propafenone in volunteers.

H Müller-Peltzer, G Greger, G Neugebauer, M Hollmann.   

Abstract

The chemical structure of propafenone (P) and certain experimental findings suggest that this antiarrhythmic compound could possess beta-blocking properties. To evaluate the clinical relevance of the latter cardiovascular effects of P during exercise were studied. After oral administration of P 150 and 300 mg in solution, six healthy volunteers were subjected to graded exercise. These doses of P, which are usually effective against arrhythmias, decreased exercise-induced tachycardia, whereas the systolic blood pressure was lowered but only at rest, and the diastolic pressure was slightly raised. However, taking into account dose ratio, and the intensity and duration of the reduction in exercise tachycardia, this effect of P was only about 5% at its maximum compared to propranolol and similar active beta-blocking compounds. The reduction in heart rate produced by P was not correlated with the plasma level nor did it show dose dependency, in contrast to beta-blocking agents, and also in contrast to its electrophysiological effects on the PQ interval.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6662183     DOI: 10.1007/bf00542530

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

Review 1.  The assessment of beta-adrenoceptor blocking drugs in man.

Authors:  D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

2.  The effects of a new beta-adrenoceptive receptor blocking drug on heart rate in man.

Authors:  R C Hill; P Turner
Journal:  Br J Pharmacol Chemother       Date:  1968-03

3.  [Pharmacology of 2'-[2-hydroxy-3-(propylamino)-propoxy]-3-phenylpropiophenone (Propafenone, SA 79)-hydrochloride].

Authors:  H J Hapke; E Prigge
Journal:  Arzneimittelforschung       Date:  1976

4.  [Plasma level and effectiveness of propafenone and its organ distribution (author's transl)].

Authors:  H Blanke; B Aschbrenner; K R Karsch; H Kreuzer
Journal:  Dtsch Med Wochenschr       Date:  1979-04-20       Impact factor: 0.628

5.  [Effect of the antiarrhythmic agent propaphenone on cardiac conduction. clinical studies using bundle of his electrography].

Authors:  O A Beck; E Witt; H Hochrein
Journal:  Z Kardiol       Date:  1975-02

6.  Plasma propranolol levels in the quaniitative assessment of beta-adrenergic blockade in man.

Authors:  D J Coltart; D G Shand
Journal:  Br Med J       Date:  1970-09-26

7.  [Studies on the analysis of propafenone by means of internal analogue standardization (author's transl)].

Authors:  E Brode; R Sachse; H D Hoffmann
Journal:  Arzneimittelforschung       Date:  1982

8.  Investigations on the pharmacokinetics of propafenone in man.

Authors:  M Hollmann; E Brode; D Hotz; S Kaumeier; O H Kehrhahn
Journal:  Arzneimittelforschung       Date:  1983

9.  Electrophysiological and antiarrhythmic properties of propafenon in isolated cardiac preparations.

Authors:  F Ledda; L Mantelli; S Manzini; S Amerini; A Mugelli
Journal:  J Cardiovasc Pharmacol       Date:  1981 Nov-Dec       Impact factor: 3.105

10.  Comparison of the effects of labetalol and propranolol in healthy men at rest and during exercise.

Authors:  D A Richards; E P Woodings; J G Maconochie
Journal:  Br J Clin Pharmacol       Date:  1977-02       Impact factor: 4.335

  10 in total
  5 in total

Review 1.  Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.

Authors:  D W Harron; R N Brogden
Journal:  Drugs       Date:  1987-12       Impact factor: 9.546

2.  Stereoselective electrophysiological effects of propafenone in Langendorff perfused guinea pig hearts.

Authors:  U Stark; G Stark; K Stoschitzky; E Pilger; S Nagl; W Lindner; H A Tritthart
Journal:  Basic Res Cardiol       Date:  1992 Jan-Feb       Impact factor: 17.165

3.  Short-term and long-term treatment with propafenone: determinants of arrhythmia suppression, persistence of efficacy, arrhythmogenesis, and side effects in patients with symptoms.

Authors:  M Zehender; S Hohnloser; A Geibel; A Furtwängler; M Olschewski; T Meinertz; H Just
Journal:  Br Heart J       Date:  1992-06

Review 4.  Clinical pharmacokinetics of propafenone.

Authors:  J T Hii; H J Duff; E D Burgess
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

5.  The effects of the stereoisomers of propafenone and diprafenone in guinea-pig heart.

Authors:  K Groschner; W Lindner; H Schnedl; W R Kukovetz
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.